Systemic sclerosis & Raynaud's
Impact of autoantibody status on stratifying the risk of organ involvement and mortality in systemic sclerosis (SSc): experience from a multicentre French cohort of 1605 patients
Authors' conclusion
This study unravels, by contrast with skin phenotype, a strong association between AAbs specificities, organ involvement and outcome in SSc and suggests that patients' classification based on only skin extension is not sufficient for defining prognosis and phenotype.
Study context
- Population
- Patients with SSc followed in seven French university hospitals367 dcSSc
- Participants
- 1,605 patients
- Exposure
- Autoantibody specificities (full antinuclear panel, nine specificities) vs skin phenotype for stratifying risk of organ involvement and mortality
- Outcome
- Organ involvement and mortality
Methodological detailsmulticentre, multivariate analysis
- Multicentre
- Multivariate analysis
Main finding
As reported in the abstract
Estimate (95% CI)
ATAILD
OR 3.27(2.42–4.42)
ATAmortality
HR 1.9(1.01–3.58)
anti-RNAPIIIscleroderma renal crisis
OR 7.05(2.98–16.72)
anti-RNAPIIImortality
HR 2.35(1.12–4.93)
anti-U1RNParthritis
OR 3.79(2.16–6.67)
anti-Pm/Sclmyositis
OR 7.09(3.87–12.98)
anti-Kumyositis
OR 7.99(2.41–26.46)
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Impact of autoantibody status on stratifying the risk of organ involvement and mortality in SSc: experience from a multicentre French cohort of 1605 patients. RMD Open. Published 20 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →